| Identification | More | [Name]
10-Hydroxydecanoic acid | [CAS]
1679-53-4 | [Synonyms]
10-HYDROXYDECANOIC ACID
10-Hydroxycapricacid
Decanoic acid, 10-hydroxy-
10-HYDROXY-DECYLIC ACID
10-HYDROXYDECANOIC ACID 95% | [EINECS(EC#)]
216-848-1 | [Molecular Formula]
C10H20O3 | [MDL Number]
MFCD00010510 | [Molecular Weight]
188.26 | [MOL File]
1679-53-4.mol |
| Hazard Information | Back Directory | [Uses]
Reactant involved in: • ;Synthesis of copolymers of acrylamide and sodium acryloyloxydecanoate1• ;Macrolactonization for preparation of Sansalvamide A2• ;Studies of chain length selectivity for cutinase catalyzed polycondensation reactions3• ;Ruthenium-catalyzed esterification followed by macrocyclization4• ;Synthesis of anhydrides and esters5 | [Definition]
ChEBI: A 10-carbon, omega-hydroxy fatty acid, shown to be the preferred hydroxylation product (together with the 9-OH isomer) of capric acid in biosystems, and used as a standard in lipid assays; reported to have cytotoxic effects. | [General Description]
10-Hydroxydecanoic acid (10-HDA) is a saturated fatty acid of hydroxy-trans-2-decenoic acid (10H2DA). Its molecule has two functional groups (-OH and -COOH). It has been reported to prevent the lipopolysaccharide-induced NO production in murine macrophages. 10-HDA has been extracted from royal jelly obtained from honeybees (Apis mellifera) and exhibits estrogenic action. Its polymerization with the polyethylene glycol-modified lipase in a transparent benzene solution has been reported to proceed by the formation of ester linkage. | [in vivo]
10-Hydroxydecanoic acid (1 mol/L; Intranasal injection 100 μL; once daily for 3 days) increases the number of microfold cells (M cells) in the epithelium lining the luminal surface of the nasopharyngeal-associated lymphoid tissue (NALT) in cynomolgus monkeys[2].
10-Hydroxydecanoic acid (2.4 mg; p.o.; enteric-coated capsules taken orally once a day for 20 days) increases the number of M cells and improves the level of antigen-specific immunoglobulin A (IgA) in the follicle-associated epithelium (FAE) covering Peyer’s patches (PPs) in cynomolgus monkeys[2]. | Animal Model: | cynomolgus macaque [2] | | Dosage: | 1 mol/L, Administer 100 μL | | Administration: | Intranasal administration; once a day for 3 days | | Result: | Increased number of gp2-positive cells in the epithelium overlying NALT follicles. |
| Animal Model: | cynomolgus macaque [2] | | Dosage: | 2.4 mg | | Administration: | p.o.; enteric-coated capsules once a day for 20 days | | Result: | Increased the number of gp2-positive M cells.
10-HDAA (2.4 mg) enteric-coated capsules containing poliovirus antigen (106 TCID50) induced poliovirus- and influenza virus-specific IgAs on day 12 after oral administration. |
|
|
|